Compare SBS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBS | RVMD |
|---|---|---|
| Founded | 1954 | 2014 |
| Country | Brazil | United States |
| Employees | N/A | 883 |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2B | 19.2B |
| IPO Year | 2002 | N/A |
| Metric | SBS | RVMD |
|---|---|---|
| Price | $33.29 | $139.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $140.84 |
| AVG Volume (30 Days) | 1.3M | ★ 3.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.85 | $533.02 |
| P/E Ratio | $15.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.88 | $34.00 |
| 52 Week High | $35.79 | $155.70 |
| Indicator | SBS | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 60.59 |
| Support Level | $23.76 | $93.39 |
| Resistance Level | $35.79 | $155.70 |
| Average True Range (ATR) | 0.69 | 7.75 |
| MACD | -0.28 | -0.59 |
| Stochastic Oscillator | 14.24 | 36.30 |
Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in Sao Paulo State, and supplies treated water and sewage services on a wholesale basis. SABESP may perform activities in other states and countries and can operate in drainage, urban cleaning, solid waste handling, and energy markets. The company determined that it has a single operating segment, which is the provision of sanitation services.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.